Vyome to go public and trade on the nasdaq capital market under the ticker symbol “hind”

Cambridge, mass., july 09, 2024 (globe newswire) -- vyome therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the us and global markets with large market potential, announced today that it has signed a merger agreement with reshape lifesciences (nasdaq: rsls).
NDAQ Ratings Summary
NDAQ Quant Ranking